Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has cleared Motivista, a smartphone-based prescription digital therapeutic, making it the first FDA-authorized treatment targeting the negative symptoms of schizophrenia — like avolition, anhedonia, and asociality. Developed by Click Therapeutics, it's used for 16 weeks as an add-on to antipsychotic medication. A phase III trial showed a 62% relative improvement in negative symptom severity compared to controls.
The FDA has granted 510(k) clearance to Motivista (CT-155), a prescription digital therapeutic developed by Click Therapeutics — marking a historic first: the only FDA-authorized treatment specifically targeting the negative symptoms of schizophrenia. While existing treatments manage hallucinations, delusions, and disorganized thinking (positive symptoms), conditions like avolition (lack of motivation), anhedonia (inability to feel pleasure), and asociality have had no approved therapies — until now.
Motivista is delivered via smartphone over 16 weeks as an adjunct to clinician-managed antipsychotic care. It uses CBT-based techniques including cognitive restructuring, behavioral activation, social skills training, and positive affect training — essentially bringing structured psychotherapy to patients' fingertips. It's designed only for patients whose positive symptoms are already stable and who are actively on antipsychotics.
By the Numbers:
Why it matters: Negative symptoms are a major driver of long-term disability and healthcare costs in schizophrenia, yet they've been largely untreatable — until now. With Medicaid covering a large share of this population, state-level coverage decisions will be pivotal in determining whether patients can actually access this breakthrough tool.
